Analysis of the current state of frailty indexes and their implementation for aging intervention studies.

Animal lifespan studies are foundational to developing interventions against the biological aging process. In recent years, there has been rising interest in characterizing the effects of longevity therapeutics on health span. Frailty indexes, originally developed to assess clinical frailty in aging humans, have shown promise as measurements of biological age and have been adopted for use in rodent aging biology.

Cell-Surface LAMP1 is a Senescence Marker in Aging and Idiopathic Pulmonary Fibrosis.

The accumulation of senescent cells (SEN) with aging produces a chronic inflammatory state that accelerates age-related diseases. Eliminating SEN has been shown to delay, prevent, and in some cases reverse aging in animal disease models and extend lifespan. There is thus an unmet clinical need to identify and target SEN while sparing healthy cells.

The demographic and biomedical case for late-life interventions in aging.

The social and medical costs of the biological aging process are high and will rise rapidly in coming decades, creating an enormous challenge to societies worldwide. In recent decades, researchers have expanded their understanding of the underlying deleterious structural and physiological changes (aging damage) that underlie the progressive functional impairments, declining health, and rising mortality of aging humans and other organisms and have been able to intervene in the process in model organisms, even late in life. To preempt a global aging crisis, we advocate an ambitious global initiative to translate these findings into interventions for aging humans, using three complementary approaches to retard, arrest, and even reverse aging damage, extending and even restoring the period of youthful health and functionality of older people.

You don't need a weatherman: famines, evolution, and intervention into aging.

Calorie restriction (CR) is the most robust available intervention into biological aging. Efforts are underway to develop pharmaceuticals that would replicate CR's anti-aging effects in humans ("CR mimetics"), on the assumption that the life- and healthspan-extending effects of CR in lower organisms will be proportionally extrapolable to humans (the "proportionality principle" (PP)). A recent argument from evolutionary theory (the "weather hypothesis" (WH)) suggests that CR (or its mimetics) will only provide 2-3 years of extended healthy lifespan in humans.